Core Viewpoint - Polyrizon Ltd. is advancing its development of intranasal Naloxone, a treatment for opioid overdose, through preclinical studies utilizing its Trap and Target™ platform, which aims to enhance drug delivery and effectiveness [1][3][4]. Company Overview - Polyrizon is a development stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, which create a barrier in the nasal cavity against viruses and allergens [6]. - The company is also developing its Capture and Contain (C&C) hydrogel technology, which aims to improve bioadhesion and retention for drug delivery [6]. Industry Context - The opioid crisis is a significant global public health emergency, with a rise in overdose fatalities largely driven by synthetic opioids like fentanyl [4]. - The global Naloxone market is projected to reach $2.47 billion by 2032, with a compound annual growth rate (CAGR) of 11% [4]. - The intranasal Naloxone spray market is expected to reach $1.4 billion by 2030 [4]. Product Development - The preclinical studies will evaluate key parameters such as drug loading capacity, release kinetics, nasal deposition, and stability, which are essential for future safety and efficacy testing [3]. - The proprietary T&T platform is designed to optimize drug delivery, potentially increasing bioavailability and ensuring rapid opioid reversal in emergency situations [4][5].
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform